Rapid Micro Biosystems (RPID) Net Cash Flow Growth (3y) (2023 - 2026)

Rapid Micro Biosystems (RPID) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -32.51%
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -87.87%
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 31.32%
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -11.49%
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -87.88%
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 129.29%
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -48.90%
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -65.12%
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Rapid Micro Biosystems 90.41 Mn 80.98 Mn 371,000.00 -32.79%

Historic Data

Download Data
DateValue
Mar 31, 2026 -32.79%
Dec 31, 2025 -4.18%
Sep 30, 2025 26.53%
Jun 30, 2025 62.87%
Mar 31, 2025 26.35%
Dec 31, 2024 50.32%
Sep 30, 2024 -28.59%
Jun 30, 2024 55.33%
Mar 31, 2024 -26.49%
Dec 31, 2023 -52.83%
Sep 30, 2023 18.34%